Información del artículo
Abstract
The major objectives of tuberculosis (TB) control are to reduce morbidity and mortality via an early and appropriate treatment of the disease, to prevent carriers of the Mycobacterium tuberculosis bacillus from transmitting it to others, and to prevent latent tuberculosis infection (LTB) sufferers from progressing to the disease. To achieve these objectives, it is imperative to start an appropriate, effective antituberculosis treatment as early as possible, as well as identify contacts of the infected TB patient and others at risk of LTB progressing to TB, in order to establish an appropriate treatment for them. Here we review the bases for treating TB and LTB infections, including those produced by strains resistant to anti-TB drugs.
Keywords:
Tuberculosis
Latent tuberculosis infection
Extensively drug-resistant tuberculosis
Multi-drug-resistant tuberculosis
Antituberculosis treatment
Resumen
El objetivo del control de la tuberculosis (TB) es reducir su morbilidad y mortalidad mediante el tratamiento precoz y adecuado de la enfermedad, la prevención de la transmisión de Mycobacterium tuberculosis desde personas bacilíferas y la prevención de la progresión a enfermedad de personas con infección latente tuberculosa (ILT). Para alcanzar estos objetivos se requieren el inicio precoz y la correcta cumplimentación de un tratamiento antituberculoso efectivo, y la identificación de contactos de pacientes con TB infectante y de otras personas con ILT con riesgo de progresar a enfermedad tuberculosa para establecer el tratamiento adecuado de estas personas. Revisamos las bases del tratamiento de la TB y de la ILT, incluyendo las producidas por cepas resistentes a los fármacos antituberculosos.
Palabras clave:
Tuberculosis
Infección latente tuberculosa
Tuberculosis extensamente resistente
Tuberculosis multirresistente
Tratamiento antituberculoso
El Texto completo está disponible en PDF
References
[1.]
American Thoracic Society Documents. ATS/CDC/IDSA.
Treatment of tuberculosis.
Am J Respir Crit Care Med, 167 (2003), pp. 603-662
[2.]
P. Coll.
Active drugs against Mycobacterium tuberculosis.
Enferm Infecc Microbiol Clin, 27 (2009), pp. 474-480
[3.]
J. González-Martín, J.M. García-García, L. Anibarro, R. Vidal, J. Esteban, R. Blanquer, et al.
Documento de consenso sobre diagnóstico, tratamiento y prevención de la tuberculosis.
Enf Infecc Microbiol Clin, 28 (2010), pp. e1-20
[4.]
L. Wayne.
Dormancy of Mycobacterium tuberculosis and latency of disease.
EurJ Clin Microbiol Infect Dis, 13 (1994), pp. 908-914
[5.]
H.L. David.
Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis.
Appl Microbiol, 20 (1970), pp. 810-814
[6.]
A. Domínguez-Castellano, A. Del Arco, J. Canueto-Quintero, A. Rivero-Román, J.M. Kindelán, R. Creagh, et al.
Guía de práctica clínica de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI) sobre el tratamiento de la tuberculosis.
Enferm Infecc Microbiol Clin, 25 (2007), pp. 519-534
[7.]
Consenso Nacional para el Control de la Tuberculosis en España.
Grupo de Trabajo sobre Tuberculosis.
Med Clin (Barc), 98 (1992), pp. 24-31
[8.]
World Health Organisation. Global Tuberculosis Programmes. Treatment of tuberculosis: guidelines for national programmes. (WHO/CDS/TB/2003.13). Genève: World Health Organisation; 2003.
[9.]
J.Y. Wang, J.T. Wang, T.H. Tsai, C.L. Hsu, C.J. Yu, P.R. Hsueh, et al.
Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis.
Int J Tuberc Lung Dis, 14 (2010), pp. 65-71
[10.]
M.B. Conde, A. Efron, C. Loredo, G.R. De Souza, N.P. Graça, M.C. Cezar, et al.
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
Lancet, 373 (2009), pp. 1183-1189
[11.]
S.E. Dorman, J.L. Johnson, S. Goldberg, G. Muzanye, N. Padayatchi, L. Bozeman, et al.
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
Am J Respir Crit Care Med, 180 (2009), pp. 273-280
[12.]
A. Rivero, M. Márquez, J. Santos, A. Pinedo, M.A. Sánchez, A. Esteve, et al.
High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B.
Clin Infect Dis, 32 (2001), pp. 159-161
[13.]
J.S. Mukherjee, M.L. Rich, A.R. Socci, J.K. Joseph, F.A. Virú, S.S. Shin, et al.
Programmes and principles in treatment of multidrug-resistant tuberculosis.
Lancet, 363 (2004), pp. 474-481
[14.]
Revised definition of extensively drug resistant tuberculosis. MMWR Morb Mortal Wkly Rep. 2006;55:1176.
[15.]
CDC.
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection.
MMWR, 49 (2000), pp. 1-71
[16.]
S.H. Ferebee.
Controlled chemoprophylaxis trials in tuberculosis: a general review.
Adv Tuberc Res, 17 (1970), pp. 28-106
[17.]
International Union Against Tuberculosis Committee on Prophylaxis.
Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial.
Bull WHO, 60 (1982), pp. 555-564
[18.]
Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council.
A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong.
Am Rev Respir Dis, 145 (1992), pp. 36-41
[19.]
K.R. Page, F. Sifakis, R. Montes de Oca, W.A. Cronin, M.C. Doherty, L. Federline, et al.
Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
Arch Intern Med, 166 (2006), pp. 1863-1870
[20.]
A. Lardizabal, M. Passannante, F. Kojakali, C. Hayden, L.B. Reichman.
Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.
Chest, 130 (2006), pp. 1712-1717
[21.]
D. Menzies, R. Long, A. Trajman, M.J. Dion, J. Yang, Al Jahdali, et al.
Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.
Ann Intern Med, 149 (2008), pp. 689-697
[22.]
P.D. Ziakas, E. Mylonakis.
4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.
Clinical Infectious Diseases, 49 (2009), pp. 1883-1889
[23.]
E. Martínez Alfaro, J. Solera, E. Serna, D. Cuenca, M.L. Castillejos, A. Espinosa, et al.
Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis [in Spanish].
Med Clin (Barc), 111 (1998), pp. 401-404
[24.]
C.C. Whalen, J.L. Johnson, A. Okwera, D.L. Hom, R. Huebner, P. Mugyenyi, et al.
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus.
N Engl J Med, 337 (1997), pp. 801-808
[25.]
A. Rivero, L. López-Cortés, R. Castillo, J. Verdejo, M.A. García, F.J. Martínez-Marcos, et al.
Ensayo clínico aleatorizado para evaluar tres pautas cortas de tratamiento de la infección latente tuberculosa en pacientes infectados por el VIH.
Enferm Infecc Microbiol Clin, 25 (2007), pp. 305-310
[26.]
A. Rivero, L. López-Cortés, R. Castillo, F. Lozano, M.A. García, F. Díez, et al.
Ensayo clínico aleatorizado de tres pautas de quimioprofilaxis para prevenir la tuberculosis en pacientes infectados por el VIH con anergia cutánea.
Enferm Infecc Microbiol Clin, 21 (2003), pp. 287-292
[27.]
J. Ena, V. Valls.
Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.
Clinical Infectious Diseases, 40 (2005), pp. 670-676
[28.]
F. Gordin, R.E. Chaisson, J.P. Matts, C. Miller, M. De Lourdes García, R. Hafner, et al.
Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
JAMA, 283 (2000), pp. 1445-1450
[29.]
CDC.
Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations.
MMWR, 47 (1998), pp. 1-58
[30.]
P.P. Cook, R.A. Maldonado, C.T. Yarnell, D. Holbert.
Safety and completion rate of shortcourse therapy for treatment of latent tuberculosis infection.
Clin Infect Dis, 43 (2006), pp. 271-275
[31.]
CDC.
Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC Recommendations.
MMWR, 50 (2001), pp. 733-735
[32.]
R.M. Jasmer, J.J. Saukkonen, H.M. Blumberg, C.L. Daley, J. Bernardo, E. Vittinghoff, et al.
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Ann Intern Med, 137 (2002), pp. 640-647
[33.]
L. McNeill, M. Allen, C. Estrada, P. Cook.
Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
Chest, 123 (2003), pp. 102-106
[34.]
X.F. Gao, L. Wang, G.J. Liu, J. Wen, X. Sun, Y. Xie, et al.
Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Int J Tuberc Lung Dis, 10 (2006), pp. 1080-1090
[35.]
N.A. Halsey, J.S. Coberly, J. Desormeaux, P. Losikoff, J. Atkinson, L.H. Moulton, et al.
Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
Lancet, 351 (1998), pp. 786-792
[36.]
A. Mwinga, M. Hosp, P. Godfrey-Faussett, M. Quigley, P. Mwaba, B.N. Mugala, et al.
Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.
Aids, 12 (1998), pp. 2447-2457
[37.]
A. Camacho, I. Pérez-Camacho, A. Rivero, C. Natera, M. García-Lázaro, J.J. Castón, et al.
Usar rifampicina más pirazinamida en profilaxis antituberculosa no incrementa el riesgo de hepatotoxicidad grave en pacientes infectados por virus de la inmunodeficiencia humana: metaanálisis de ensayos clínicos aleatorizados y controlados.
Enferm Infecc Microbiol Clin, 28 (2010), pp. 239-244
Copyright © 2011. Elsevier España S.L.. All rights reserved
